

February 11, 2013

Colorado House of Representatives
House Health Committee

Dear Committee Members:

If the FDA has determined the interchangeability of the Biological and the Biosimilar, it would be wrong not to allow the substitution to take place.

In as much as the patient and the physician are to be made aware of the change it should allow for a decrease in the cost of treating many patients with cancer.

Dr. Ira S. Jaffrey, F.A.C.P.
Practicing Oncologist, Glenwood Springs, CO
Internal Medicine Board Certified
Medical Oncology Board Certified
University of Colorado Health Sciences Center Assistant Clinical Professor (active)
Columbia Presbyterian College of Physicians and Surgeons Academic Appointment (retired)
Mount Sinai School of Medicine Academic Appointment (retired)